Therapeutic vaccination in chronic hepatitis B: Preclinical studies in the woodchuck model

Journal of Viral Hepatitis

Volumn 14, Issue SUPPL. 1, 2007, Pages 51-57

  Roggendorf, M ^a   Schulte, I ^a   Xu, Y ^a   Lu, M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Anti viral therapy; Hepatitis B virus; Immunotherapy; Therapeutic vaccination; Woodchuck hepatitis virus; Woodchuck model

Indexed keywords

CLEVUDINE; DNA VACCINE; FAMCICLOVIR; HEPATITIS ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PHOSPHORYL LIPID A; PLASMID DNA;

ADJUVANT THERAPY; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL THERAPY; B LYMPHOCYTE; CELL SPECIFICITY; CONFERENCE PAPER; DISEASE SEVERITY; DRUG MEGADOSE; GENE REPRESSION; HEPATITIS B; HEPATITIS VIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; MONITORING; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; VACCINATION; VIRUS REPLICATION; WOODCHUCK;

ANIMALS; DISEASE MODELS, ANIMAL; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; IMMUNOTHERAPY, ACTIVE; MARMOTA;

EID: 35449001014     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00914.x     Document Type: Conference Paper

References (53)

1. Janssen HL, Van Zonneveld M, Senturk H et al. Rotterdam foundation for liver research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005 365: 123 129.
2. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005 352: 2682 2695.
3. Raney AK, Hamatake RK, Hong Z. Agents in clinical development for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2003 12: 1281 1295.
4. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006 44: 422 431.
5. Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000 156: 1117 1132.
6. Rehermann B. Immune responses in hepatitis B virus infection. Semin Liver Dis 2003 23: 21 38.
7. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005 5: 215 229.
8. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients recovery from acute viral hepatitis despite active maintainance of a cytotoxic T-lymphocyte response. Nat Med 1996 2: 1104 1108.
9. Penna A, Artini M, Cavalli A et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996 98: 1185 1194.
10. Pol S, Driss F, Carnot F et al. Vaccination against hepatitis B virus: an efficient immunotherapy against hepatitis B multiplication. C R Acad Sci III 1993 316: 688 691.
11. Pol S, Driss F, Michel ML et al. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994 344: 342.
12. Pol S. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Biomed Pharmacother 1995 49: 105 109.
13. Pol S, Couillin I, Michel ML et al. Immunotherapy of chronic hepatitis B by anti-HBV vaccine. Acta Gastroenterol Belg 1998 61: 228 233.
14. Pol S, Nalpas B, Driss F et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001 34: 917 921.
15. Wen YM, Wu XH, Hu DC et al. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 1995 345: 1575 1576.
16. Yalcin K, Acar M, Degertekin H. Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection 2003 31: 221 225.
17. Couillin I, Pol S, Mancini M et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999 180: 15 26.
18. Jung MC, Gruner N, Zachoval R et al. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferation response in chronic hepatitis B carriers. Vaccine 2002 20: 3598 3612.
19. Dikici B, Kalayci AG, Ozgenc F et al. Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr Infect Dis J 2003 22: 345 349.
20. Horiike N, Fazle SM, Michitaka K et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 2005 32: 156 161.
21. Safadi R, Isreali E, Papa O et al. Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol 2003 98: 2505 2515.
22. Guidotti LG, Rochford R, Chung J et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999 284: 825 829.
23. Thimme R, Wieland S, Steiger C et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003 77: 68 76.
24. Tang TJ, Kwekkeboom J, Mancham S et al. Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. J Hepatol 2005 43: 45 52.
25. Maini MK, Boni C, Lee CK et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000 191: 1269 1280.
26. Roggendorf M, Tolle TK. The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology 1995 38: 100 112.
27. Lu M, Roggendorf M. Evaluation of new approaches to prophylactic and therapeutic vaccinations against hepatitis B viruses in the woodchuck model. Intervirology 2001 44: 124 131.
28. Roggendorf M, Lu M. Woodchuck hepatitis virus. In: Thomas TH, Zuckermann A, Lemon S, eds. Viral Hepatitis, 3rd edn. Oxford: Blackwell Publishing Ltd, 2005: 210 224.
29. Roggendorf M, Lu M. Therapeutic vaccination in chronic hepadnavirus infection. In: Dogner E, Holzenburg A, eds. New Concepts of Antiviral Therapy. Berlin Heidelberg New York: Springer, 2006: 3 20.
30. Lu M, Menne S, Yang D, Xu Y, Roggendorf M. Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model. Expert Opin Investig Drugs 2007 16: 787 801.
31. Menne S, Maschke J, Lu M, Grosse-Wilde H, Roggendorf M. T-cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge. J Virol 1998 72: 6083 6091.
32. Menne S, Roneker CA, Roggendorf M, Gerin JL, Cote PJ, Tennant BC. Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation. J Virol 2002 76: 1769 1780.
33. Frank I, Budde C, Fiedler M et al. Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide. J Virol 2007 81: 7156 7163.
34. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002 2: 735 747.
35. Betts MR, Brenchley JM, Price DA et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003 281: 65 78.
36. Rubio V, Stuge TB, Singh N et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003 9: 1377 1382.
37. Zelinskyy G, Robertson SJ, Schimmer S, Messer RJ, Hasenkrug KJ, Dittmer U. CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection. J Virol 2005 79: 10619 10626.
38. Webster GJ, Reignat S, Maini MK et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000 32: 1117 1124.
39. Hervas-Stubbes S, Lasarte JJ, Sarobe P et al. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J Hepatol 1997 27: 726 736.
40. Hervas-Stubbes S, Berassain C, Golvano JJ et al. Overcoming class II-linked non-responsiveness to hepatitis B vaccine. Vaccine 1994 12: 867 871.
41. Lu M, Klaes R, Menne S et al. Induction of antibodies to the preS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens. J Hepatol 2003 39: 405 413.
42. Hervas-Stubbes S, Lasarte JJ, Sarobe P et al. T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. J Hepatol 2001 35: 105 111.
43. Menne S, Roneker CA, Korba BE et al. Breaking T cell tolerance in chronic WHV infection by vaccination with WHsAg alone and in combination with the antiviral drug LFMAU. Antiviral Ther 2000 5: B58.
44. Menne S, Roneker CA, Tennant BC et al. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology 2002 45: 237 250.
45. Menne S, Roneker CA, Korba BE et al. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-l- arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 2002 76: 5305 5314.
46. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998 102: 968 976.
47. Boni C, Penna A, Ogg GS et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001 33: 963 971.
48. Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003 39: 595 605.
49. Korba BE, Cote PJ, Menne S et al. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir Ther 2004 9: 937 952.
50. Tennant BC, Tsohkov IA, Peek SF et al. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 2004 127: 283 293.
51. Zheng BJ, Ng MH, He LF et al. Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice. Vaccine 2001 19: 4219 4225.
52. Xu DZ, Huang KL, Zhao K et al. Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 2005 23: 2658 2664.
53. Yao X, Zheng B, Zhou J et al. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 2007 25 (10 1771 1779.